Study Title
A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma
Study Details
Description:
Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years after diagnosis. To improve survival, researchers need to find ways to identify returning disease earlier. Objective: To find out if the radiotracer 18F-fluciclovine (a substance injected into the blood during imaging scans) is better at detecting MM than the one (18F-FDG) currently used for this purpose.
Sponsor:
National Cancer Institute
Contacts:
NCI Medical Oncology Referral Officencimo_referrals@nih.gov
(888) 624-1937
Elizabeth M Hill, M.D. (Principal Investigator)elizabeth.hill@nih.gov
(240) 889-5377
Government Study Link:
NCT06103838 - Click here to see study onClinicalTrials.gov
© 2021 XCancer Software LLC
Contact XCancer: 402-991-8468